{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:53:35Z","timestamp":1794815615061,"version":"4.9.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41584-023-01042-z","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T19:01:55Z","timestamp":1699038115000},"page":"778-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Treatment of systemic juvenile idiopathic arthritis"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9247-4729","authenticated-orcid":false,"given":"Claas H.","family":"Hinze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1946-3916","authenticated-orcid":false,"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"1042_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","volume":"8","author":"A Martini","year":"2022","unstructured":"Martini, A. et al. Juvenile idiopathic arthritis. Nat. Rev. Dis. Prim. 8, 5 (2022).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1042_CR2","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty, R. E. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390\u2013392 (2004).","journal-title":"J. Rheumatol."},{"key":"1042_CR3","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1002\/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C","volume":"43","author":"LR Spiegel","year":"2000","unstructured":"Spiegel, L. R. et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 43, 2402\u20132409 (2000).","journal-title":"Arthritis Rheum."},{"key":"1042_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic, P. A. et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat. Rev. Rheumatol. 17, 257\u2013269 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1042_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/art.41107","volume":"72","author":"C Kessel","year":"2020","unstructured":"Kessel, C., Hedrich, C. M. & Foell, D. Innately adaptive or truly autoimmune: is there something unique about systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 72, 210\u2013219 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/art.40099","volume":"69","author":"C Kessel","year":"2017","unstructured":"Kessel, C. et al. Proinflammatory cytokine environments can drive interleukin-17 overexpression by \u03b3\/\u03b4 T cells in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 69, 1480\u20131494 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132508","volume":"5","author":"LA Henderson","year":"2020","unstructured":"Henderson, L. A. et al. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight 5, e132508 (2020).","journal-title":"JCI Insight"},{"key":"1042_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.42409","volume":"75","author":"J Kuehn","year":"2023","unstructured":"Kuehn, J. et al. Aberrant naive CD4-positive T cell differentiation in systemic juvenile idiopathic arthritis committed to B cell help. Arthritis Rheumatol. 75, 826\u2013841 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert, S. J. et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 66, 1034\u20131043 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze, C. H. et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr. Rheumatol. Online J. 16, 7 (2018).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1042_CR11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt, E. M. et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. 64, 1001\u20131010 (2012).","journal-title":"Arthritis Care Res."},{"key":"1042_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini, A. et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus. J. Rheumatol. 46, 190\u2013197 (2019).","journal-title":"J. Rheumatol."},{"key":"1042_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000074","volume":"1","author":"C Sengler","year":"2015","unstructured":"Sengler, C. et al. The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort. RMD Open\u00a01, e000074 (2015).","journal-title":"RMD Open"},{"key":"1042_CR14","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","volume":"74","author":"J Guzman","year":"2015","unstructured":"Guzman, J. et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann. Rheum. Dis. 74, 1854\u20131860 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/BOR.0000000000000526","volume":"30","author":"S Yasin","year":"2018","unstructured":"Yasin, S. & Schulert, G. S. Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment. Curr. Opin. Rheumatol. 30, 514\u2013520 (2018).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1042_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/rheumatology\/37.11.1240","volume":"37","author":"AO Adebajo","year":"1998","unstructured":"Adebajo, A. O. & Hall, M. A. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br. J. Rheumatol. 37, 1240\u20131242 (1998).","journal-title":"Br. J. Rheumatol."},{"key":"1042_CR17","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385\u20132395 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR18","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto, N. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2396\u20132406 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar, N. M. et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 71, 1163\u20131173 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR20","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","volume":"77","author":"N Ruperto","year":"2018","unstructured":"Ruperto, N. et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann. Rheum. Dis. 77, 1710\u20131719 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR21","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1002\/art.39796","volume":"68","author":"J Klotsche","year":"2016","unstructured":"Klotsche, J. et al. Outcome and trends in treatment of systemic juvenile idiopathic arthritis in the German National Pediatric Rheumatologic Database, 2000-2013. Arthritis Rheumatol. 68, 3023\u20133034 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/art.41612","volume":"73","author":"M Pardeo","year":"2021","unstructured":"Pardeo, M. et al. Early treatment and IL1RN single-nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 73, 1053\u20131061 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier, P. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70, 747\u2013754 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR24","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","volume":"66","author":"NT Ilowite","year":"2014","unstructured":"Ilowite, N. T. et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 66, 2570\u20132579 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel, K. B. et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 74, 553\u2013569 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12969-021-00597-z","volume":"19","author":"RG Peterson","year":"2021","unstructured":"Peterson, R. G., Xiao, R., Katcoff, H., Fisher, B. T. & Weiss, P. F. Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data. Pediatr. Rheumatol. Online J. 19, 109 (2021).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1042_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12969-022-00768-6","volume":"20","author":"T Beukelman","year":"2022","unstructured":"Beukelman, T. et al. First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Pediatr. Rheumatol. Online J. 20, 113 (2022).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1042_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"HI Brunner","year":"2018","unstructured":"Brunner, H. I. et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann. Rheum. Dis. 77, 21\u201329 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR29","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","volume":"326","author":"EH Giannini","year":"1992","unstructured":"Giannini, E. H. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children\u2019s Study Group. N. Engl. J. Med. 326, 1043\u20131049 (1992).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell, D. J. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342, 763\u2013769 (2000).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR31","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell, D. J. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359, 810\u2013820 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR32","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMoa041810","volume":"352","author":"E Silverman","year":"2005","unstructured":"Silverman, E. et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N. Engl. J. Med. 352, 1655\u20131666 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto, N. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372, 383\u2013391 (2008).","journal-title":"Lancet"},{"key":"1042_CR34","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","volume":"43","author":"P Woo","year":"2000","unstructured":"Woo, P. et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 43, 1849\u20131857 (2000).","journal-title":"Arthritis Rheum."},{"key":"1042_CR35","first-page":"2353","volume":"21","author":"ED Silverman","year":"1994","unstructured":"Silverman, E. D. et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J. Rheumatol. 21, 2353\u20132358 (1994).","journal-title":"J. Rheumatol."},{"key":"1042_CR36","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jpeds.2004.08.020","volume":"145","author":"TJ Lehman","year":"2004","unstructured":"Lehman, T. J. et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J. Pediatr. 145, 856\u2013857 (2004).","journal-title":"J. Pediatr."},{"key":"1042_CR37","first-page":"47","volume":"64","author":"AA Maksimov","year":"1992","unstructured":"Maksimov, A. A., Sha\u012dkov, A. V., Speranski\u012d, A. I. & Solov\u2019ev, S. K. Pulse therapy with methylprednisolone and cyclophosphamide in systemic juvenile rheumatoid arthritis: the results of an open, parallel, controlled, randomized, 12-month study [Russian]. Ter. Arkh. 64, 47\u201351 (1992).","journal-title":"Ter. Arkh."},{"key":"1042_CR38","first-page":"599","volume":"24","author":"N Ruperto","year":"2006","unstructured":"Ruperto, N. et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG\/PRINTO phase IV post marketing surveillance study. Clin. Exp. Rheumatol. 24, 599\u2013605 (2006).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1042_CR39","doi-asserted-by":"publisher","first-page":"109143","DOI":"10.1016\/j.clim.2022.109143","volume":"245","author":"PT Oommen","year":"2022","unstructured":"Oommen, P. T. et al. Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): new perspectives on interdisciplinary care. Clin. Immunol. 245, 109143 (2022).","journal-title":"Clin. Immunol."},{"key":"1042_CR40","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22087","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold, S. et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res. 65, 1551\u20131563 (2013).","journal-title":"Arthritis Care Res."},{"key":"1042_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJM196701052760102","volume":"276","author":"JJ Calabro","year":"1967","unstructured":"Calabro, J. J. & Marchesano, J. M. Fever associated with juvenile rheumatoid arthritis. N. Engl. J. Med. 276, 11\u201318 (1967).","journal-title":"N. Engl. J. Med."},{"key":"1042_CR42","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1093\/rheumatology\/keab729","volume":"61","author":"C Park","year":"2022","unstructured":"Park, C. et al. MRP8\/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Rheumatology 61, 3082\u20133092 (2022).","journal-title":"Rheumatology"},{"key":"1042_CR43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","volume":"61","author":"M Shimizu","year":"2013","unstructured":"Shimizu, M., Nakagishi, Y. & Yachie, A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 61, 345\u2013348 (2013).","journal-title":"Cytokine"},{"key":"1042_CR44","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1002\/art.24137","volume":"58","author":"H Wittkowski","year":"2008","unstructured":"Wittkowski, H. et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 58, 3924\u20133931 (2008).","journal-title":"Arthritis Rheum."},{"key":"1042_CR45","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/art.24349","volume":"60","author":"M Frosch","year":"2009","unstructured":"Frosch, M. et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1\u03b2 form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 883\u2013891 (2009).","journal-title":"Arthritis Rheum."},{"key":"1042_CR46","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","volume":"66","author":"PA Nigrovic","year":"2014","unstructured":"Nigrovic, P. A. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 66, 1405\u20131413 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/bjh.18413","volume":"199","author":"NJ Fordham","year":"2022","unstructured":"Fordham, N. J. et al. What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis? Br. J. Haematol. 199, 447\u2013451 (2022).","journal-title":"Br. J. Haematol."},{"key":"1042_CR48","first-page":"1665","volume":"66","author":"MS Tamashiro","year":"2011","unstructured":"Tamashiro, M. S. et al. Discrimination of acute lymphoblastic leukemia from systemic-onset juvenile idiopathic arthritis at disease onset. Clinics 66, 1665\u20131669 (2011).","journal-title":"Clinics"},{"key":"1042_CR49","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/acr.21889","volume":"65","author":"Y Kimura","year":"2013","unstructured":"Kimura, Y. et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res. 65, 745\u2013752 (2013).","journal-title":"Arthritis Care Res."},{"key":"1042_CR50","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","volume":"78","author":"VE Saper","year":"2019","unstructured":"Saper, V. E. et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann. Rheum. Dis. 78, 1722\u20131731 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR51","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","volume":"71","author":"GS Schulert","year":"2019","unstructured":"Schulert, G. S. et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 71, 1943\u20131954 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR52","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.42137","volume":"74","author":"BA Binstadt","year":"2022","unstructured":"Binstadt, B. A. & Nigrovic, P. A. The conundrum of lung disease and drug hypersensitivity-like reactions in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 74, 1122\u20131131 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR53","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","volume":"81","author":"VE Saper","year":"2022","unstructured":"Saper, V. E. et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann. Rheum. Dis. 81, 406\u2013415 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR54","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.42099","volume":"74","author":"G Chen","year":"2022","unstructured":"Chen, G. et al. Identification of distinct inflammatory programs and biomarkers in systemic juvenile idiopathic arthritis and related lung disease by serum proteome analysis. Arthritis Rheumatol. 74, 1271\u20131283 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR55","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/acr.25126","volume":"75","author":"EM Behrens","year":"2023","unstructured":"Behrens, E. M. UnDRESSing systemic juvenile idiopathic arthritis lung disease. Arthritis Care Res. 75, 2033\u20132035 (2023).","journal-title":"Arthritis Care Res."},{"key":"1042_CR56","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/acr.25132","volume":"75","author":"AM Lerman","year":"2023","unstructured":"Lerman, A. M. et al. HLA-DRB1*15 and eosinophilia are common among patients with systemic juvenile idiopathic arthritis. Arthritis Care Res. 75, 2082\u20132087 (2023).","journal-title":"Arthritis Care Res."},{"key":"1042_CR57","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/acr.25129","volume":"75","author":"H Wobma","year":"2023","unstructured":"Wobma, H. et al. Incidence and risk factors for eosinophilia and lung disease in biologic-exposed children with systemic juvenile idiopathic arthritis. Arthritis Care Res. 75, 2063\u20132072 (2023).","journal-title":"Arthritis Care Res."},{"key":"1042_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/art.42656","author":"RGA Erkens","year":"2023","unstructured":"Erkens, R. G. A. et al. Recombinant interleukin-1 receptor antagonist is an effective first-line treatment strategy in new-onset systemic juvenile idiopathic arthritis, irrespective of HLA-DRB1 background and IL1RN variants. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42656 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR59","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1080\/07853890.2022.2095431","volume":"54","author":"WG Ambler","year":"2022","unstructured":"Ambler, W. G., Nanda, K., Onel, K. B. & Shenoi, S. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives. Ann. Med. 54, 1839\u20131850 (2022).","journal-title":"Ann. Med."},{"key":"1042_CR60","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2021.06.003","volume":"47","author":"R Erkens","year":"2021","unstructured":"Erkens, R., Esteban, Y., Towe, C., Schulert, G. & Vastert, S. Pathogenesis and treatment of refractory disease courses in systemic juvenile idiopathic arthritis: refractory arthritis, recurrent macrophage activation syndrome and chronic lung disease. Rheum. Dis. Clin. North Am. 47, 585\u2013606 (2021).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"1042_CR61","doi-asserted-by":"publisher","unstructured":"Schulert, G. S. & Kessel, C. Molecular pathways in the pathogenesis of systemic juvenile idiopathic arthritis. Rheum. Dis. Clin. North Am. https:\/\/doi.org\/10.1016\/j.rdc.2023.06.007 (2023).","DOI":"10.1016\/j.rdc.2023.06.007"},{"issue":"Suppl. 1","key":"1042_CR62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12969-020-00444-7","volume":"18","author":"SW Canna","year":"2020","unstructured":"Canna, S. W. et al. Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatr. Rheumatol. Online J. 18 (Suppl. 1), 53 (2020).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1042_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05489-7","volume":"9","author":"A Jain","year":"2018","unstructured":"Jain, A., Song, R., Wakeland, E. K. & Pasare, C. T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells. Nat. Commun. 9, 3185 (2018).","journal-title":"Nat. Commun."},{"key":"1042_CR64","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5152\/eurjrheum.2016.055","volume":"4","author":"M Lee","year":"2017","unstructured":"Lee, M. & Isaacs, J. The novel use of combined IL-1 and IL-6 inhibition in a patient with severe, aggressive, erosive, systemic-onset juvenile idiopathic arthritis. Eur. J. Rheumatol. 4, 68\u201369 (2017).","journal-title":"Eur. J. Rheumatol."},{"key":"1042_CR65","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3899\/jrheum.100726","volume":"38","author":"JL Record","year":"2011","unstructured":"Record, J. L., Beukelman, T. & Cron, R. Q. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J. Rheumatol. 38, 180\u2013181 (2011).","journal-title":"J. Rheumatol."},{"key":"1042_CR66","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/rheumatology\/kez284","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin, S. et al. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology 59, 442\u2013445 (2020).","journal-title":"Rheumatology"},{"key":"1042_CR67","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/annrheumdis-2022-eular.2275","volume":"81","author":"E Alveyn","year":"2022","unstructured":"Alveyn, E. & Rutherford, A. Combination anakinra and tocilizumab to treat refractory macrophage activation syndrome triggered by adult-onset Still\u2019s disease [abstract OP0194]. Ann. Rheum. Dis. 81, 128\u2013129 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10875-022-01353-y","volume":"43","author":"JE Rood","year":"2023","unstructured":"Rood, J. E. et al. Improvement of refractory systemic juvenile idiopathic arthritis-associated lung disease with single-agent blockade of IL-1\u03b2 and IL-18. J. Clin. Immunol. 43, 101\u2013108 (2023).","journal-title":"J. Clin. Immunol."},{"key":"1042_CR69","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes, I. B. et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res. Ther. 21, 183 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1042_CR70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka, Y., Luo, Y., O\u2019Shea, J. J. & Nakayamada, S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat. Rev. Rheumatol. 18, 133\u2013145 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1042_CR71","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/rheumatology\/keab673","volume":"61","author":"EL Verweyen","year":"2022","unstructured":"Verweyen, E. L. & Schulert, G. S. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA). Rheumatology 61, 926\u2013935 (2022).","journal-title":"Rheumatology"},{"key":"1042_CR72","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1164\/rccm.201903-0659OC","volume":"201","author":"E Verweyen","year":"2020","unstructured":"Verweyen, E. et al. Synergistic signaling of TLR and IFN\u03b1\/\u03b2 facilitates escape of IL-18 expression from endotoxin tolerance. Am. J. Respir. Crit. Care Med. 201, 526\u2013539 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1042_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216983","volume":"81","author":"B Bader-Meunier","year":"2022","unstructured":"Bader-Meunier, B. et al. Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report. Ann. Rheum. Dis. 81, e20 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR74","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03000439 (2023)."},{"key":"1042_CR75","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04088396 (2023)."},{"key":"1042_CR76","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.4049\/jimmunol.1700352","volume":"198","author":"Q Zhu","year":"2017","unstructured":"Zhu, Q. & Kanneganti, T. D. Cutting edge: distinct regulatory mechanisms control proinflammatory cytokines IL-18 and IL-1\u03b2. J. Immunol. 198, 4210\u20134215 (2017).","journal-title":"J. Immunol."},{"key":"1042_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34480-6","volume":"13","author":"Z Huang","year":"2022","unstructured":"Huang, Z. et al. mTORC1 links pathology in experimental models of Still\u2019s disease and macrophage activation syndrome. Nat. Commun. 13, 6915 (2022).","journal-title":"Nat. Commun."},{"key":"1042_CR78","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1093\/rheumatology\/keab114","volume":"60","author":"S Concha","year":"2021","unstructured":"Concha, S., Rey-Jurado, E., Poli, M. C., Hoyos-Bachiloglu, R. & Borzutzky, A. Refractory systemic juvenile idiopathic arthritis successfully treated with rapamycin. Rheumatology 60, e250\u2013e251 (2021).","journal-title":"Rheumatology"},{"key":"1042_CR79","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","volume":"30","author":"EI Alexeeva","year":"2011","unstructured":"Alexeeva, E. I. et al. Efficacy in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 30, 1163\u20131172 (2011).","journal-title":"Clin. Rheumatol."},{"key":"1042_CR80","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/rheumatology\/ken492","volume":"48","author":"M Kasher-Meron","year":"2009","unstructured":"Kasher-Meron, M., Uziel, Y. & Amital, H. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report. Rheumatology 48, 445\u2013446 (2009).","journal-title":"Rheumatology"},{"key":"1042_CR81","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/ard.2008.092106","volume":"68","author":"J Narvaez","year":"2009","unstructured":"Narvaez, J. et al. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann. Rheum. Dis. 68, 607\u2013608 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147076","volume":"131","author":"YP Zhu","year":"2021","unstructured":"Zhu, Y. P. et al. Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C. J. Clin. Invest. 131, e147076 (2021).","journal-title":"J. Clin. Invest."},{"key":"1042_CR83","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/art.22656","volume":"56","author":"DM Brinkman","year":"2007","unstructured":"Brinkman, D. M. et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum. 56, 2410\u20132421 (2007).","journal-title":"Arthritis Rheum."},{"key":"1042_CR84","doi-asserted-by":"publisher","first-page":"1123104","DOI":"10.3389\/fped.2023.1123104","volume":"11","author":"D Chellapandian","year":"2023","unstructured":"Chellapandian, D. & Milojevic, D. Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Front. Pediatr. 11, 1123104 (2023).","journal-title":"Front. Pediatr."},{"key":"1042_CR85","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","volume":"2","author":"JMF Silva","year":"2018","unstructured":"Silva, J. M. F. et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2, 777\u2013786 (2018).","journal-title":"Blood Adv."},{"key":"1042_CR86","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12969-021-00523-3","volume":"19","author":"G Morelle","year":"2021","unstructured":"Morelle, G. et al. Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 19, 27 (2021).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1042_CR87","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","volume":"3","author":"A Consolaro","year":"2019","unstructured":"Consolaro, A. et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child. Adolesc. Health 3, 255\u2013263 (2019).","journal-title":"Lancet Child. Adolesc. Health"},{"key":"1042_CR88","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13312-013-0041-0","volume":"50","author":"K Sathe","year":"2013","unstructured":"Sathe, K. & Khubchandani, R. P. Thalidomide for systemic onset juvenile idiopathic arthritis. Indian Pediatr. 50, 237\u2013239 (2013).","journal-title":"Indian Pediatr."},{"key":"1042_CR89","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jbspin.2006.12.004","volume":"74","author":"M Garcia-Carrasco","year":"2007","unstructured":"Garcia-Carrasco, M., Fuentes-Alexandro, S., Escarcega, R. O., Rojas-Rodriguez, J. & Escobar, L. E. Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine 74, 500\u2013503 (2007).","journal-title":"Joint Bone Spine"},{"key":"1042_CR90","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1067\/mpd.2002.120835","volume":"140","author":"TJ Lehman","year":"2002","unstructured":"Lehman, T. J., Striegel, K. H. & Onel, K. B. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J. Pediatr. 140, 125\u2013127 (2002).","journal-title":"J. Pediatr."},{"key":"1042_CR91","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/08830180801911339","volume":"27","author":"T Paravar","year":"2008","unstructured":"Paravar, T. & Lee, D. J. Thalidomide: mechanisms of action. Int. Rev. Immunol. 27, 111\u2013135 (2008).","journal-title":"Int. Rev. Immunol."},{"key":"1042_CR92","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00018-010-0619-9","volume":"68","author":"T Ito","year":"2011","unstructured":"Ito, T., Ando, H. & Handa, H. Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol. Life Sci. 68, 1569\u20131579 (2011).","journal-title":"Cell Mol. Life Sci."},{"key":"1042_CR93","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s12098-019-02912-9","volume":"86","author":"P Pal","year":"2019","unstructured":"Pal, P., Giri, P. P. & Sinha, R. Cyclosporine in resistant systemic arthritis \u2013 a cheaper alternative to biologics. Indian J. Pediatr. 86, 590\u2013594 (2019).","journal-title":"Indian J. Pediatr."},{"key":"1042_CR94","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00431-006-0380-0","volume":"166","author":"H Tanaka","year":"2007","unstructured":"Tanaka, H. et al. Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur. J. Pediatr. 166, 1053\u20131055 (2007).","journal-title":"Eur. J. Pediatr."},{"key":"1042_CR95","first-page":"2305","volume":"17","author":"D Wang","year":"2019","unstructured":"Wang, D., Chen, X. & Li, Z. Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus. Exp. Ther. Med. 17, 2305\u20132309 (2019).","journal-title":"Exp. Ther. Med."},{"key":"1042_CR96","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13075-016-1069-z","volume":"18","author":"F Gohar","year":"2016","unstructured":"Gohar, F., Kessel, C., Lavric, M., Holzinger, D. & Foell, D. Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks? Arthritis Res. Ther. 18, 163 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"1042_CR97","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2019-215051","volume":"78","author":"F Gohar","year":"2019","unstructured":"Gohar, F. et al. Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 78, 1107\u20131113 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR98","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1016\/S2665-9913(21)00115-6","volume":"3","author":"C Kessel","year":"2021","unstructured":"Kessel, C. et al. Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. Lancet Rheumatol. 3, e563\u2013e573 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1042_CR99","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","volume":"76","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia, C. et al. Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 76, 166\u2013172 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR100","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1093\/rheumatology\/keab113","volume":"60","author":"T Hinze","year":"2021","unstructured":"Hinze, T. et al. A dysregulated interleukin-18-interferon-\u03b3-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis. Rheumatology 60, 5165\u20135174 (2021).","journal-title":"Rheumatology"},{"key":"1042_CR101","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2011-200598","volume":"71","author":"D Holzinger","year":"2012","unstructured":"Holzinger, D. et al. The Toll-like receptor 4 agonist MRP8\/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann. Rheum. Dis. 71, 974\u2013980 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR102","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foell","year":"2010","unstructured":"Foell, D. et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. J. Am. Med. Assoc. 303, 1266\u20131273 (2010).","journal-title":"J. Am. Med. Assoc."},{"key":"1042_CR103","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2021-222029","volume":"81","author":"J Gerss","year":"2022","unstructured":"Gerss, J. et al. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Ann. Rheum. Dis. 81, 990\u2013997 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1042_CR104","doi-asserted-by":"publisher","first-page":"15970","DOI":"10.1073\/pnas.1520779112","volume":"112","author":"MJ Ombrello","year":"2015","unstructured":"Ombrello, M. J. et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc. Natl Acad. Sci. USA 112, 15970\u201315975 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1042_CR105","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/art.40498","volume":"70","author":"VL Arthur","year":"2018","unstructured":"Arthur, V. L. et al. IL1RN variation influences both disease susceptibility and response to recombinant human interleukin-1 receptor antagonist therapy in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 70, 1319\u20131330 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR106","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/art.41130","volume":"72","author":"C Hinze","year":"2020","unstructured":"Hinze, C. et al. Impact of IL1RN variants on response to interleukin-1 blocking therapy in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 72, 499\u2013505 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR107","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"AK Palucka","year":"2005","unstructured":"Palucka, A. K., Blanck, J. P., Bennett, L., Pascual, V. & Banchereau, J. Cross-regulation of TNF and IFN-\u03b1 in autoimmune diseases. Proc. Natl Acad. Sci. USA 102, 3372\u20133377 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1042_CR108","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/art.40442","volume":"70","author":"NM Ter Haar","year":"2018","unstructured":"Ter Haar, N. M. et al. Reversal of sepsis-like features of neutrophils by interleukin-1 blockade in patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumatol. 70, 943\u2013956 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1042_CR109","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/annrheumdis-2018-214354","volume":"78","author":"E Van Nieuwenhove","year":"2019","unstructured":"Van Nieuwenhove, E. et al. Machine learning identifies an immunological pattern associated with multiple juvenile idiopathic arthritis subtypes. Ann. Rheum. Dis. 78, 617\u2013628 (2019).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 10","key":"1042_CR110","first-page":"1148","volume":"72","author":"A Leek","year":"2020","unstructured":"Leek, A. et al. The SHARE recommendations on diagnosis and treatment of systemic JIA [abstract]. Arthritis Rheumatol. 72 (Suppl. 10), 1148 (2020).","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl. 2","key":"1042_CR111","first-page":"75","volume":"20","author":"C Hinze","year":"2022","unstructured":"Hinze, C. et al. Characteristics and disease course of patients with systemic juvenile idiopathic arthritis without arthritis in the German AID-NET cohort [abstract O02]. Pediatr. Rheumatol. Online J. 20 (Suppl. 2), 75 (2022).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"1042_CR112","doi-asserted-by":"publisher","unstructured":"Huang, Z. et al. Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI165616 (2023).","DOI":"10.1172\/JCI165616"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01042-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01042-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01042-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T14:25:05Z","timestamp":1700576705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01042-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":112,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01042-z","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"28 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.H.H. has received travel support from Pfizer. D.F. has received speaker fees\/honoraria from Chugai-Roche, Novartis and Swedish Orphan Biovitrum (SOBI), as well as research support from Novartis, Pfizer and SOBI, and the German Research Foundation (DFG, grant number FO 354\/14-1). C.K. has received consulting fees from Novartis and SOBI, research support from Novartis, and support from the German Research Foundation (grant number KE 2026 1\/3).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}